EMA Recommends Granting a Marketing Authorisation for Poherdy By Ogkologos - April 10, 2026 219 0 Facebook Twitter Google+ Pinterest WhatsApp It is a biosimilar of pertuzumab which was authorised in the EU in 2013 Source RELATED ARTICLESMORE FROM AUTHOR Giredestrant plus everolimus prolongs PFS among patients with ER-positive, HER2-negative, ESR1-mutated advanced breast cancer after the receipt of a CDK4/6 inhibitor EMA Recommends Granting a Marketing Authorisation for Ensartinib Taking on the RAS Challenge MOST POPULAR A Combination of Osimertinib Plus Pemetrexed and a Platinum-based Agent Significantly... November 29, 2023 First-Line Treatment with Encorafenib Plus Cetuximab Plus mFOLFOX6 Significantly Improves ORR... February 17, 2025 MAP Congress 2020: Molecular Analysis for Precision Oncology October 2, 2020 What Hodgkin Lymphoma Survivors Should Know About Mantle Radiation and Breast... June 14, 2022 Load more HOT NEWS Treatment with Brigatinib Results in Radiographic Responses and Clinical Benefit in... Neoadjuvant Nivolumab Plus Ipilimumab Shows Trend Towards Long-Term Clinical Benefit versus... Cancer Does Not Affect All People Equally: An Expert Q&A on... ESMO Gynaecological Cancers Congress 2022, 17 – 18 June 2022 Valencia,...
